| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 10.1K | 16.7% | 9.5% |
| Total Income | 10.1K | 16.7% | 9.5% |
| Expenditure | 6.5K | 9.9% | 0.3% |
| PBT | 2.8K | 32.8% | 76.5% |
| Net Profit | 2.4K | 30.6% | 65.8% |
| OPM | 34.95% | 4.02pp | 6.02pp |
| NPM | 23.62% | 2.52pp | 8.02pp |
| EPS | 4.40 | 30.6% | 65.4% |
Amgen Reports Q2 2026 Financial Results
05 Aug 2026 · 5 Aug, 1:39 am
Summary
Amgen announced strong financial results for the second quarter of 2026, with total revenues reaching $10.1 billion, a 10% increase year-over-year, driven by a 9% rise in product sales primarily due to volume growth. GAAP earnings per share saw a substantial 65% increase to $4.37, supported by higher revenues and a 6.5 percentage point expansion in GAAP operating margin to 36.8%. Non-GAAP EPS grew 4% to $6.29. The company also generated $3.5 billion in free cash flow, a significant improvement from the prior year. Management expressed confidence in continued growth, citing strong performance from key growth drivers and advancements in the pipeline.
Key Highlights
- 1
Amgen reported total revenues of $10.1 billion for the second quarter of 2026, an increase of 10% compared to the second quarter of 2025.
- 2
Product sales grew 9% year-over-year, driven by volume growth, with twenty-two products delivering at least double-digit sales growth.
- 3
GAAP earnings per share (EPS) increased 65% to $4.37 for the second quarter, driven by higher revenues.
- 4
GAAP operating income increased from $2.7 billion to $3.5 billion, and GAAP operating margin increased 6.5 percentage points to 36.8% for the second quarter.
- 5
Non-GAAP EPS increased 4% to $6.29 for the second quarter, primarily driven by higher revenues.
- 6
The Company generated $3.5 billion of free cash flow in the second quarter of 2026, a significant increase from $1.9 billion in the second quarter of 2025.
- 7
Repatha® sales increased 37% year-over-year to $953 million, and EVENITY® sales increased 38% year-over-year to $714 million in the second quarter.
Management Comments
Robert A. Bradway
Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade.
Informational and educational content only. Not investment advice.